You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLINICAL TRIALS PROFILE FOR LYOPHILIZED CYTOXAN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LYOPHILIZED CYTOXAN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006110 ↗ Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer Completed UNC Lineberger Comprehensive Cancer Center Phase 2 1998-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy, monoclonal antibody therapy, and surgery may be a more effective treatment for breast cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, monoclonal antibody therapy, and surgery in treating women who have stage II, stage III, or stage IV breast cancer.
NCT03132584 ↗ Cyclophosphamide and Alemtuzumab In Lymphoma Terminated Genzyme, a Sanofi Company Phase 1 2017-07-30 This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: - Cyclophosphamide - Alemtuzumab
NCT03132584 ↗ Cyclophosphamide and Alemtuzumab In Lymphoma Terminated Sanofi Phase 1 2017-07-30 This research study is studying a combination of chemotherapy drugs as a possible treatment for aggressive lymphoma that has not responded to standard treatment. The names of the study interventions involved in this study are: - Cyclophosphamide - Alemtuzumab
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LYOPHILIZED CYTOXAN

Condition Name

Condition Name for LYOPHILIZED CYTOXAN
Intervention Trials
Breast Cancer 1
CD52 Positive Non-Hodgkin Lymphoma 1
Diffuse Large B Cell Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LYOPHILIZED CYTOXAN
Intervention Trials
Lymphoma, B-Cell 1
Lymphoma 1
Breast Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LYOPHILIZED CYTOXAN

Trials by Country

Trials by Country for LYOPHILIZED CYTOXAN
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LYOPHILIZED CYTOXAN
Location Trials
Massachusetts 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LYOPHILIZED CYTOXAN

Clinical Trial Phase

Clinical Trial Phase for LYOPHILIZED CYTOXAN
Clinical Trial Phase Trials
Phase 2 1
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LYOPHILIZED CYTOXAN
Clinical Trial Phase Trials
Completed 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LYOPHILIZED CYTOXAN

Sponsor Name

Sponsor Name for LYOPHILIZED CYTOXAN
Sponsor Trials
UNC Lineberger Comprehensive Cancer Center 1
Genzyme, a Sanofi Company 1
Sanofi 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LYOPHILIZED CYTOXAN
Sponsor Trials
Other 2
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.